AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15187503 — intervention group
Group type: COMPARATOR
Intervention: 12 mL/kg predicted body weight tidal volume
Number of subjects: 300
Study 15187503 — intervention group
Group type: COMPARATOR
Intervention: 12.3 +/- 2.7 mL/kg tidal volume
Number of subjects: 300
Study 10776101 — intervention group
Group type: EXPERIMENTAL
Intervention: Control on Campus intervention program
Number of subjects: 3
Study 10776101 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 9401573 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, 1.0 IU/kg/day, subcutaneous injections from postnatal day 7 until body weight of 2000 g (postnatal week 7-8)
Number of subjects: 14
Study 9401573 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 14
Study 9401573 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 14
Study 8397245 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mmol/24 h sodium supplement
Number of subjects: 17
Study 8397245 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 17
Study 8397245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake
Number of subjects: 17
Study 2427042 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal lavage
Number of subjects: 39
Study 2427042 — intervention group
Group type: COMPARATOR
Intervention: Standard care in the ICU
Number of subjects: 39
Study 31957303 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP + MTX
Number of subjects: 316
Study 31957303 — intervention group
Group type: COMPARATOR
Intervention: PBO + MTX
Number of subjects: 316
Study 29016985 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem Elite with etched teeth (Group 1, IME)
Number of subjects: 1098
Study 29016985 — intervention group
Group type: COMPARATOR
Intervention: Maxcem Elite with non-etched teeth (Group 2, IMNE)
Number of subjects: 1098
Study 29016985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexus+Excite (Group 3, INE)
Number of subjects: 1098
Study 29016985 — intervention group
Group type: EXPERIMENTAL
Intervention: Relyx (Group 4, IRE)
Number of subjects: 1098
Study 29016985 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem Elite with silicatized base (Group 5, HRME)
Number of subjects: 1098
Study 29016985 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem Elite with non-silicatized base (Group 6, HNRME)
Number of subjects: 1098
Study 25773504 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Supreme
Number of subjects: 90
Study 25773504 — intervention group
Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 90
Study 24895454 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg daily; 15 mg if creatinine clearance <50 mL/min)
Number of subjects: 6229
Study 24895454 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (target international normalized ratio=2.0‐3.0)
Number of subjects: 6229
Study 22005747 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training plus usual care (n = 65)
Number of subjects: 98
Study 22005747 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n = 33)
Number of subjects: 98
Study 20546516 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection PVB followed by CPVB infusion of 0.1% or 0.2% ropivacaine
Number of subjects: 73
Study 20546516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 73
Study 17915572 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose creatine (60 mg/kg/day)
Number of subjects: 10
Study 17915572 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose (75 g prior to exercise)
Number of subjects: 10
Study 17915572 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 16264044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year smoking cessation in COPD patients
Number of subjects: 53
Study 16264044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year smoking cessation in asymptomatic smokers
Number of subjects: 53
Study 11875168 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD400 (budesonide, 200 microg twice daily via pMDI and NebuChamber)
Number of subjects: 40
Study 11875168 — intervention group
Group type: EXPERIMENTAL
Intervention: FP400 (fluticasone propionate, 200 microg twice daily via pMDI and Babyhaler)
Number of subjects: 40
Study 11875168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11875168 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between BUD400 and FP400
Number of subjects: 40
Study 10203139 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (E2) supplementation at 2.30 mg x kg(‐1) x d(‐1) (1.13‐3.42 mg x kg(‐1) x d(‐1)) and progesterone (P) supplementation at 21.20 mg x kg(‐1) x d(‐1) (11.23‐27.36 mg x kg(‐1) x d(‐1))
Number of subjects: 13
Study 7775364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50‐100 mg/day)
Number of subjects: 286
Study 7775364 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20‐40 mg/day)
Number of subjects: 286
Study 1927983 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip bumpers fabricated from stainless steel round wire covered with shrink tubing, activated every 2 to 3 months
Number of subjects: 40
Study 1927983 — intervention group
Group type: COMPARATOR
Intervention: Larger prefabricated lip bumpers covered with acrylic shields from canine to canine, activated every 4 to 5 weeks
Number of subjects: 40
Study 6364678 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetic formulation EMLA (lidocaine-prilocaine cream)
Number of subjects: 119
Study 30902694 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 165
Study 30902694 — intervention group
Group type: COMPARATOR
Intervention: Travoprost
Number of subjects: 165
Study 30902694 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 165
Study 29247457 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG + MPA + CC
Number of subjects: 320
Study 29247457 — intervention group
Group type: COMPARATOR
Intervention: hMG + MPA
Number of subjects: 320
Study 24132592 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor mother support programme
Number of subjects: 63
Study 22626879 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV), n=19
Number of subjects: 42
Study 22626879 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV), n=18
Number of subjects: 42
Study 22626879 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 42
Study 22626879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide therapy (ETV and ADV)
Number of subjects: 42
Study 19608838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 15 mg
Number of subjects: 129
Study 19608838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg
Number of subjects: 129
Study 17524196 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-delivered partner medication (PDPM)
Number of subjects: 106
Study 17524196 — intervention group
Group type: COMPARATOR
Intervention: Patient-based partner referral (PBPR)
Number of subjects: 106
Study 15235555 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol and remifentanil
Number of subjects: 120
Study 15235555 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sciatic-femoral nerve block
Number of subjects: 120
Study 15235555 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 120
Study 11465522 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (10 to 30 mg b.i.d.)
Number of subjects: 102
Study 11465522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 9471066 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-locking suture loop configuration per suture strand
Number of subjects: 0
Study 9471066 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-locking suture loop configuration per suture strand
Number of subjects: 0
Study 9471066 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-grasping suture loop configuration per suture strand
Number of subjects: 0
Study 9471066 — intervention group
Group type: EXPERIMENTAL
Intervention: Single locking configuration per strand
Number of subjects: 0
Study 8190152 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise training
Number of subjects: 100
Study 8190152 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplementation
Number of subjects: 100
Study 8190152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with exercise
Number of subjects: 100
Study 3300587 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 61
Study 3300587 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 61
Study 29106516 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 0
Study 29106516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26895303 — intervention group
Group type: EXPERIMENTAL
Intervention: HBP telemonitoring system
Number of subjects: 60
Study 26895303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 24101420 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol
Number of subjects: 52
Study 24101420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21861637 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingivally applied glycine powder air polishing (SubGPAP)
Number of subjects: 30
Study 21861637 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth glycine powder air polishing (full-mouth GPAP)
Number of subjects: 30
Study 21861637 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 30
Study 20855784 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-length stockings
Number of subjects: 3114
Study 20855784 — intervention group
Group type: COMPARATOR
Intervention: Below-knee stockings
Number of subjects: 3114
Study 18216861 — intervention group
Group type: EXPERIMENTAL
Intervention: Early minimal enteral nutrition from day 2 to day 7
Number of subjects: 84
Study 18216861 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 84
Study 15989452 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg/kg by intravenous infusion (IV)
Number of subjects: 160
Study 15989452 — intervention group
Group type: EXPERIMENTAL
Intervention: IV fentanyl 0.25 microg/kg
Number of subjects: 160
Study 15989452 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive dressing and IV fentanyl 0.25 microg/kg
Number of subjects: 160
Study 15989452 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo cream and IV fentanyl 0.25 microg/kg
Number of subjects: 160
Study 15989452 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream and IV fentanyl 0.25 microg/kg
Number of subjects: 160
Study 15989452 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo cream and IV fentanyl 0.25 microg/kg with an occlusive dressing
Number of subjects: 160
Study 15989452 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream and IV fentanyl 0.25 microg/kg with an occlusive dressing
Number of subjects: 160
Study 14500150 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (25 mL 0.25% bupivacaine and piroxicam 20 mg)
Number of subjects: 90
Study 14500150 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (25 mL saline)
Number of subjects: 90
Study 14500150 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (25 mL 0.25% bupivacaine)
Number of subjects: 90
Study 10909489 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment with supplementary chemotherapy (EEP cycle: Etoposide, Epirubicin, Cisplatin or 5-fluorouracil)
Number of subjects: 33
Study 10909489 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment with supplementary chemotherapy
Number of subjects: 33
Study 10909489 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers and patients after ventricular resection due to chronic peptic ulcer disease)
Number of subjects: 33
Study 8778851 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MT), 5 mg, 2300 h, D6‐D8
Number of subjects: 7
Study 8778851 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light (BL), 2,000 lx, 0800‐1200 h, D7‐D8
Number of subjects: 7
Study 8778851 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin + Bright Light (MT+BL)
Number of subjects: 7
Study 8778851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P), 2300 h, D6‐D8
Number of subjects: 7
Study 1734574 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectopexy alone (group 1)
Number of subjects: 18
Study 1734574 — intervention group
Group type: COMPARATOR
Intervention: Rectopexy with sigmoidectomy (group 2)
Number of subjects: 18
Study 6716468 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief daily telephone calls
Number of subjects: 0
Study 6716468 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 31206313 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg for 7 days
Number of subjects: 100
Study 31206313 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 100
Study 30030268 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Number of subjects: 261
Study 30030268 — intervention group
Group type: COMPARATOR
Intervention: No platelet transfusion (Control)
Number of subjects: 261
Study 27639082 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 μg)
Number of subjects: 15
Study 24727815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (6 mg/m2/day)
Number of subjects: 1947
Study 24727815 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (60 mg/m2/day)
Number of subjects: 1947
Study 22105898 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 68
Study 22105898 — intervention group
Group type: COMPARATOR
Intervention: Single chemotherapy
Number of subjects: 68
Study 22105898 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT
Number of subjects: 68
Study 20192935 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic local anesthesia with 2% lidocaine
Number of subjects: 90
Study 20192935 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren suppository placed in rectum an hour before biopsy
Number of subjects: 90
Study 20192935 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 90
Study 18334829 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIRI (pemetrexed 500 mg/m² and irinotecan 350 mg/m²)
Number of subjects: 130
Study 18334829 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (irinotecan 180 mg/m², leucovorin 200 mg/m², bolus 5-FU 400 mg/m², 5-FU 600 mg/m² infusion)
Number of subjects: 130
Study 16286517 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily for 24 weeks
Number of subjects: 89
Study 16286517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 12022381 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (Plavix)
Number of subjects: 0
Study 12022381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9863851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle changes (10% fat whole foods vegetarian diet, aerobic exercise, stress management training, smoking cessation, group psychosocial support) for 5 years
Number of subjects: 48
Study 9863851 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 48
Study 8534620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (60 mg)
Number of subjects: 4168
Study 8534620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4168
Study 2212376 — intervention group
Group type: COMPARATOR
Intervention: Benazepril
Number of subjects: 29
Study 2212376 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol OROS
Number of subjects: 29
Study 2212376 — intervention group
Group type: COMPARATOR
Intervention: Combination of benazepril and metoprolol OROS
Number of subjects: 29
Study 2212376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2212376 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 29
Study 842986 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary biliary cirrhosis patients
Number of subjects: 4
Study 842986 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiocopper studies in primary biliary cirrhosis patients
Number of subjects: 4
Study 842986 — intervention group
Group type: EXPERIMENTAL
Intervention: 64Cu in ceruloplasmin study
Number of subjects: 4
Study 30739385 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART initiation (intervention group)
Number of subjects: 0
Study 30739385 — intervention group
Group type: COMPARATOR
Intervention: Control group (before intervention)
Number of subjects: 0
Study 28247406 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitii training programme
Number of subjects: 102
Study 28247406 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 102
Study 26265174 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with prior cancer
Number of subjects: 3336
Study 26265174 — intervention group
Group type: COMPARATOR
Intervention: Participants without prior cancer
Number of subjects: 3336
Study 23138859 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight (LW) mesh
Number of subjects: 110
Study 23138859 — intervention group
Group type: COMPARATOR
Intervention: Heavyweight (HW) mesh
Number of subjects: 110
Study 21675889 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA‐TT
Number of subjects: 1501
Study 21675889 — intervention group
Group type: COMPARATOR
Intervention: PsACWY
Number of subjects: 1501
Study 19291356 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multivitamin tablet containing vitamin D(2) 400 IU (10 microg) for 6 months.
Number of subjects: 8
Study 19291356 — intervention group
Group type: COMPARATOR
Intervention: Control group of age-matched burned children without vitamin D supplementation.
Number of subjects: 8
Study 17034441 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 75 mg
Number of subjects: 18
Study 17034441 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 18
Study 17034441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12768070 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (rHuGH) therapy at a dose of 0.2 IU/kg/BW
Number of subjects: 20
Study 12768070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11152056 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment according to TCM principles (n = 20)
Number of subjects: 38
Study 11152056 — intervention group
Group type: COMPARATOR
Intervention: Control group (acupuncture points not specific for asthma, n = 18)
Number of subjects: 38
Study 9359442 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopically-directed biopsies
Number of subjects: 2798
Study 9359442 — intervention group
Group type: COMPARATOR
Intervention: Anti-inflammatory therapy
Number of subjects: 2798
Study 8251028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 6
Study 8251028 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 6
Study 8251028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ranitidine and chlorpheniramine
Number of subjects: 6
Study 8251028 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 6
Study 3765637 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine brine concentrate
Number of subjects: 50
Study 3765637 — intervention group
Group type: COMPARATOR
Intervention: Isotonic NaCl (Control)
Number of subjects: 50
Study 31102000 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐18‐FLT PET/CT
Number of subjects: 52
Study 31102000 — intervention group
Group type: COMPARATOR
Intervention: F‐18‐FDG PET/CT
Number of subjects: 52
Study 29312660 — intervention group
Group type: EXPERIMENTAL
Intervention: Latrines with ESBL-producing microorganisms
Number of subjects: 70
Study 29312660 — intervention group
Group type: COMPARATOR
Intervention: Latrines without ESBL-producing microorganisms
Number of subjects: 70
Study 27334385 — intervention group
Group type: EXPERIMENTAL
Intervention: FMR1 premutation carriers (PC)
Number of subjects: 397
Study 27334385 — intervention group
Group type: EXPERIMENTAL
Intervention: FMR1 premutation carriers (PC) with FXTAS
Number of subjects: 397
Study 27334385 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 397
Study 24906863 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications
Number of subjects: 607
Study 24906863 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 607
Study 22397614 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led dementia educational intervention for GPs (two educational sessions from a peer GP or nurse)
Number of subjects: 2000
Study 22397614 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led dementia educational intervention for GPs
Number of subjects: 2000
Study 22397614 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group receiving RACGP Guidelines by post
Number of subjects: 2000
Study 20979935 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa/entacapone (LCE) 200
Number of subjects: 0
Study 20979935 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release levodopa/carbidopa (CR-LC) 200
Number of subjects: 0
Study 18923991 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobex Spray (CP spray)
Number of subjects: 77
Study 18923991 — intervention group
Group type: COMPARATOR
Intervention: Olux Foam (CP foam)
Number of subjects: 77
Study 15961302 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 60
Study 15961302 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral plus parenteral feeding
Number of subjects: 60
Study 15961302 — intervention group
Group type: COMPARATOR
Intervention: Only parenteral feeding
Number of subjects: 60
Study 15961302 — intervention group
Group type: COMPARATOR
Intervention: TPN therapy
Number of subjects: 60